Comparative Analysis of Cerebrolysin and Edaravone as Neuroprotective Agents in Traumatic Brain Injury Recovery
Main Article Content
Abstract
Traumatic brain injury (TBI) is a major cause of neurological disability worldwide, often leading to long-term cognitive and functional impairments. This study evaluates the efficacy and safety of two neuroprotective agents, cerebrolysin and edaravone, in the recovery of patients with moderate to severe TBI. A prospective, randomized, controlled clinical trial was conducted with 150 patients divided into three groups: a Control group receiving standard care, a Cerebrolysin group, and an Edaravone group. Patients were assessed using the Glasgow Coma Scale (GCS), Glasgow Outcome Scale (GOS), and Mini-Mental State Examination (MMSE) to measure improvements in consciousness, functional independence, and cognitive function. Results indicated that both cerebrolysin and edaravone were effective in enhancing TBI recovery, but cerebrolysin demonstrated superior outcomes. The Cerebrolysin group showed the highest improvements in GCS, GOS, and MMSE scores, suggesting enhanced neuroprotection and cognitive recovery. The mean hospital stay was also shortest for the Cerebrolysin group, highlighting potential benefits in recovery speed. This study supports the use of cerebrolysin as an effective treatment for TBI, with benefits in neurological, functional, and cognitive recovery. Further research is recommended to explore long-term outcomes and combination therapies to optimize TBI management.